| Date Filed | Type | Description |
| 11/12/2021 |
SC 13D/A
| Ampersand 2018 Limited Partnership reports a 38.9% stake in INTERPACE BIOSCIENCES, INC. |
| 05/18/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/19/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/17/2020 |
4
| Ampersand 2018 Limited Partnership (10% Owner) has filed a Form 4 on INTERPACE BIOSCIENCES, INC.|
Txns:
| Disposed/sold 270 convertible preferred
@ $0
Granted 27,000 convertible preferred
@ $0
Granted 1,000 convertible preferred
@ $1000, valued at
$1M
|
|
| 01/17/2020 |
SC 13D/A
| Ampersand 2018 Limited Partnership reports a 39.4% stake in INTERPACE BIOSCIENCES, INC. |
| 10/18/2019 |
4
| Ampersand 2018 Limited Partnership (10% Owner) has filed a Form 4 on Interpace Diagnostics Group, Inc.|
Txns:
| Granted 130 convertible preferred
@ $100000, valued at
$13M
|
|
| 10/15/2019 |
4
| Ampersand 2018 Limited Partnership (10% Owner) has filed a Form 4 on Interpace Diagnostics Group, Inc.|
Txns:
| Granted 80 convertible preferred
@ $0
Disposed/sold 80 convertible preferred
@ $0 |
|
| 07/25/2019 |
SC 13D
| Ampersand 2018 Limited Partnership reports a 19.6% stake in INTERPACE DIAGNOSTICS GROUP, INC. |
| 07/25/2019 |
3
| Ampersand 2018 Limited Partnership (10% Owner) has filed a Form 3 on Interpace Diagnostics Group, Inc. |
| 03/15/2018 |
D
| Form D - Notice of Exempt Offering of Securities: |